Profile data is unavailable for this security.
About the company
ECO Animal Health Group plc is a United Kingdom-based global animal health company. The Company is focused on improving the health and welfare of pigs and poultry. It is engaged in developing and marketing branded veterinary pharmaceuticals globally, in antibiotics and vaccines for pigs and poultry. The Company is focused on providing solutions to respiratory and enteric diseases in pigs and poultry. Its segment includes the United Kingdom, China and Japan, North America, South and Southeast Asia, Latin America, Europe, and the Rest of the World. It provides products for swine and poultry to treat illness, improving health and performance. The Company’s lead product, Aivlosin, is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. It also offers a range of products to treat parasites in cattle, sheep and pigs under the brand name Ecomectin.
- Revenue in GBP (TTM)85.81m
- Net income in GBP3.02m
- Incorporated1984
- Employees219.00
- LocationECO Animal Health Group PLCThe Grange100 The High Street, SouthgateLONDON N14 6BNUnited KingdomGBR
- Phone+44 208 447 8899
- Fax+44 208 447 9292
- Websitehttps://www.ecoanimalhealthgroupplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cinclus Pharma Holding publ AB | 4.68m | -14.98m | 66.23m | 21.00 | -- | 2.24 | -- | 14.15 | -3.95 | -3.95 | 1.23 | 7.79 | 0.1002 | -- | 5.00 | 2,736,714.00 | -32.06 | -63.39 | -38.12 | -84.13 | -- | -- | -320.11 | -1,135.74 | -- | -- | 0.0209 | -- | 1,154.80 | -- | -9.49 | -- | -- | -- |
| Accent Microcell Ltd | 22.63m | 2.82m | 67.52m | 192.00 | 22.69 | 3.32 | 21.31 | 2.98 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Eco Animal Health Group Plc | 85.81m | 3.02m | 69.11m | 219.00 | 24.20 | 0.8155 | 8.66 | 0.8054 | 0.0422 | 0.0422 | 1.24 | 1.25 | 0.7605 | 2.67 | 3.38 | 391,840.20 | 4.52 | 3.90 | 5.78 | 5.38 | 49.06 | 45.20 | 5.95 | 5.17 | 2.75 | 42.11 | 0.052 | 6.51 | -10.99 | 2.00 | 60.88 | -15.42 | 11.67 | -- |
| Biostem Technologies Inc | 175.39m | 15.07m | 69.47m | 67.00 | 6.15 | 1.86 | 4.56 | 0.3961 | 0.9019 | 0.9019 | 11.60 | 2.98 | 2.82 | 2.61 | 4.65 | -- | 24.25 | -- | 55.07 | -- | 97.33 | -- | 8.59 | -- | 4.09 | -- | 0.0566 | -- | 1,708.93 | -- | 475.86 | -- | -- | -- |
| Venus Remedies Ltd | 56.99m | 6.21m | 70.91m | 1.30k | 11.41 | -- | 8.72 | 1.24 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Immuno-Biological Laboratories Co., Ltd. | 4.89m | 1.72m | 71.29m | 58.00 | 41.33 | 8.53 | 39.35 | 14.58 | 39.07 | 39.07 | 110.76 | 189.25 | 0.5456 | 0.8603 | 4.81 | 17,786,030.00 | 19.25 | -4.96 | 22.46 | -5.77 | 70.35 | 62.70 | 35.27 | -11.27 | 3.96 | 2,702.08 | 0.0947 | -- | 18.71 | 10.95 | 33.40 | -- | -- | -- |
| TAIKO PHARMACEUTICAL CO LTD | 30.32m | 4.37m | 71.52m | 214.00 | 16.22 | 1.76 | 12.69 | 2.36 | 18.37 | 18.37 | 127.34 | 169.51 | 0.5080 | 1.77 | 2.62 | -- | 7.34 | -18.99 | 9.32 | -24.04 | 54.42 | 40.20 | 14.44 | -46.31 | 2.72 | -- | 0.0874 | -- | 1.67 | -- | 2.78 | -- | -- | -- |
| Pak Fah Yeow International Ltd | 18.98m | 6.77m | 71.91m | 100.00 | 10.63 | 1.07 | 9.72 | 3.79 | 0.2277 | 0.2277 | 0.6386 | 2.26 | 0.2227 | 1.84 | 24.74 | 1,877,594.00 | 7.94 | 5.03 | 8.68 | 5.24 | 87.44 | 82.23 | 35.66 | 23.92 | 6.21 | 7.72 | 0.0068 | 94.02 | -8.64 | 9.89 | -25.14 | 16.88 | 16.37 | -8.84 |
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management Ltd.as of 08 Dec 2025 | 12.84m | 18.95% |
| SFM UK Management LLPas of 05 Aug 2025 | 7.26m | 10.71% |
| FIL Investment Advisors (UK) Ltd.as of 30 Jun 2025 | 5.94m | 8.77% |
| Lombard Odier Asset Management (Europe) Ltd.as of 30 Jun 2025 | 4.55m | 6.71% |
| Canaccord Genuity Wealth Ltd.as of 24 Aug 2022 | 3.38m | 5.00% |
| AXA Investment Managers UK Ltd.as of 21 Mar 2025 | 3.35m | 4.95% |
| Chelverton Asset Management Ltd.as of 30 Jun 2025 | 3.13m | 4.61% |
| Killik & Co. LLPas of 16 Jan 2026 | 2.00m | 2.96% |
| Danske Bank A/S (Investment Management)as of 07 Feb 2023 | 1.85m | 2.74% |
| Artemis Investment Management LLPas of 30 Jun 2025 | 1.69m | 2.49% |
